Pulmonale Hypertonie

No abstract is available for this paper.

• Publication year

  2019

• Venue

  AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie

• Publication date

  2019-05-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s10405-004-0016-x
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Self-reported functional status predicts post-operative outcomes in non-cardiac surgery patients with pulmonary hypertension

  2018cited by this paper
• In‐hospital outcomes of transcatheter mitral valve repair with Mitraclip in patients with pulmonary hypertension: Insights from the National Inpatient Sample

  2018cited by this paper
• 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension.

  2016cited by this paper
• Transcatheter creation of a reverse Potts shunt in a patient with severe pulmonary arterial hypertension associated with Moyamoya syndrome.

  2015cited by this paper
• Pulmonary hypertension and its management in patients undergoing non‐cardiac surgery

  2015cited by this paper
• Riociguat for pulmonary arterial hypertension associated with congenital heart disease

  2015cited by this paper
• Selexipag for the Treatment of Pulmonary Arterial Hypertension.

  2014cited by this paper
• Pediatric pulmonary hypertension.

  2013cited by this paper
• [Pulmonary hypertension].

  2012influential reference
• Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey

  2012cited by this paper
• Improved Survival Among Patients With Eisenmenger Syndrome Receiving Advanced Therapy for Pulmonary Arterial Hypertension

  2010cited by this paper
• Updated clinical classification of pulmonary hypertension.

  2009cited by this paper
• Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality.

  2005cited by this paper
• Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.

  2003cited by this paper
• Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents.

  2002cited by this paper
• Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension.

  2002cited by this paper
• BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives

  2002cited by this paper
• A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION

  2000cited by this paper
• Recent advances in the treatment of pediatric pulmonary artery hypertension.

  1999cited by this paper
• Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

  1995cited by this paper
• Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

  1993cited by this paper
• An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.

  1992cited by this paper
• Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

  1991cited by this paper
• Primary pulmonary hypertension.

  1987cited by this paper

• Pulmonale Hypertonie: anästhesiologisches Management

  2019cites this paper
• MRT-basierte Flussmessungen im Truncus pulmonalis zur Detektion einer pulmonal-arteriellen Hypertonie in Patienten mit zystischer Fibrose

  2008cites this paper